皓元医药(688131) - 2022 Q3 - 季度财报

Financial Performance - The company's revenue for Q3 2022 was ¥348,854,594.13, representing a 44.77% increase year-over-year[6]. - Net profit attributable to shareholders for Q3 2022 was ¥41,466,989.23, a decrease of 15.34% compared to the same period last year[6]. - The net profit after deducting non-recurring gains and losses for Q3 2022 was ¥32,040,541.26, down 31.07% year-over-year[6]. - For the first three quarters of 2022, the company achieved total revenue of 970 million RMB, a year-on-year increase of 39.38%[20]. - The net profit attributable to shareholders for the same period was 158 million RMB, representing a year-on-year growth of 9.63%, and a 25.49% increase when excluding the impact of equity incentives[20]. - In Q3 2022, the company reported revenue of 349 million RMB and a net profit of 41.47 million RMB, with a 3.30% year-on-year growth in net profit after excluding equity incentives[20]. - The company reported a net profit margin improvement, with net profit for the first three quarters of 2022 showing a significant increase compared to the previous year[41]. - The net profit for the current period is CNY 155,926,398.04, an increase from CNY 143,926,979.85 in the previous period, representing a growth of approximately 8.8%[44]. - The total profit for the current period is CNY 168,455,421.98, slightly down from CNY 169,934,416.48 in the previous period[44]. - The operating profit stands at CNY 167,437,231.19, compared to CNY 170,205,778.88 in the previous period, indicating a decrease of about 1.5%[44]. - The company reported a total comprehensive income of CNY 161,633,635.24, up from CNY 143,772,651.48 in the previous period, reflecting an increase of approximately 12.4%[46]. Research and Development - R&D investment for Q3 2022 totaled ¥58,835,045.62, an increase of 128.06% compared to the same period last year[10]. - R&D investment accounted for 16.87% of revenue in Q3 2022, up 6.16 percentage points year-over-year[10]. - The company attributed the decrease in net profit to increased R&D spending and expansion of personnel to enhance operational capabilities[18]. - The company is actively expanding its R&D capabilities and production capacity to meet growing business demands, with significant investments in various research centers and production facilities[20]. - The company continues to focus on innovation and R&D as core drivers of growth, enhancing its operational capabilities across multiple locations[20]. - Research and development expenses increased significantly to CNY 141,552,468.37 in 2022 from CNY 68,923,395.62 in 2021, reflecting a growth of approximately 105.5%[41]. Assets and Liabilities - The company's total assets as of the end of Q3 2022 were ¥2,791,332,605.55, reflecting a 17.06% increase from the end of the previous year[10]. - The total assets of the company reached 2.791 billion RMB, up 17.06% from the end of the previous year, while the net assets attributable to shareholders increased by 8.39% to 1.975 billion RMB[20]. - Total liabilities increased to CNY 803,856,587.34 from CNY 548,110,908.44, representing a growth of approximately 46.5%[39]. - The company's equity attributable to shareholders rose to CNY 1,975,265,767.03, up from CNY 1,822,307,191.98, indicating an increase of about 8.4%[39]. - Cash and cash equivalents increased to CNY 1,617,861,693.43 from CNY 1,590,489,175.71, showing a growth of approximately 1.7%[37]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥148,541,803.99, a decrease of 819.69% compared to the previous year[10]. - Cash flow from operating activities generated a net outflow of CNY -148,541,803.99, contrasting with a net inflow of CNY 20,639,578.34 in the previous period[52]. - Cash inflow from investment activities totaled CNY 2,362,178,677.98, significantly higher than CNY 277,744.00 in the previous period[52]. - The company incurred cash outflows from investment activities amounting to CNY 2,909,029,781.05, compared to CNY 117,299,204.62 in the previous period[52]. - The net cash flow from financing activities was CNY 129,014,429.99, a decrease from CNY 1,048,560,115.42 in the previous period[54]. - The cash and cash equivalents at the end of the period were CNY 482,621,162.96, down from CNY 1,230,868,931.51 in the previous period[54]. Employee Growth - As of the end of the reporting period, the company had 2,785 employees, an increase of 1,299 employees compared to the end of the previous year, primarily in technical roles[20]. Strategic Focus - The company is deepening its participation in domestic and international market competition through a globalized and brand-focused development strategy[20]. - The company plans to expand its market presence and invest in new product development to drive future growth[41]. - The company has increased its short-term borrowings to CNY 101,573,233.87 from CNY 6,000,000.00, indicating a strategic move to leverage financing for growth initiatives[37].